Amal Therapeutics to publish R&D outcomes in JCI Insight

Geneva, Switzerland, April 24, 2019 – Amal Therapeutics announced today that part of its recent research findings about its self-adjuvanted chimeric protein vaccin platform, named KISIMA™, is on line on the JCI Insight website on Wednesday April 24. This publication describe the KISIMA™ efficacy in several murine tumor models (with model-, neo- and self-antigens),  its safety and its ability to elicit a break of tolerance and antigen-specific T-cell immune responses in non-human primates.